Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome ac...
Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation
About this item
Full title
Author / Creator
Hu, Jiaxin , Xu, Jiamin , Tan, Xi , Li, Dong , Yao, Dejiang , Xu, Biao and Lei, Yuhua
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Dilated cardiomyopathy (DCM) is the major cause of heart failure and has a poor prognosis. The accumulating evidence points to an essential role of the inflammatory component in the process of DCM. Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are widely used to treat heart failure patients due to their cardiac benefits. However, their role...
Alternative Titles
Full title
Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244283
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244283
Other Identifiers
ISSN
0028-1298
E-ISSN
1432-1912
DOI
10.1007/s00210-023-02409-5
